Orthopedic devices are used to treat the disorders and injuries of the musculoskeletal system of human body. Orthobiologics are biomaterials used in orthopedic surgery as an adjunct to faster fusion and healing of the bone. Bone Grafts and Substitutes are used in surgical procedures of bones in the human body under two cases either when there is a breakage in the bone or in the case of a void between or in the bones due to number of factors such as age and degenerative diseases. GlobalData uses proprietary data and analytics to provide a comprehensive report on the bone grafts and substitutes market in Finland. Buy the latest report here.

In 2022, GlobalData’s Market Model methodology determined that the leading player in the bone grafts and substitutes market in Finland was Bioventus followed by Medtronic, NuVasive, Osiris Therapeutics, Stryker and Zimmer Biomet.

Understanding market size can be crucial to evaluate opportunities and make informed decisions about market entry and exit. Medical device companies can identify attractive segments in respective markets as well as develop marketing strategies based on forecasts for those segments.

Bone graft substitutes are synthetic substances which are an alternative to bone allografts and autografts. Allograft Bone Chips, Bone Morphogenetic Proteins (BMP), Demineralized Bone Matrix (DBM), synthetic bone substitutes, and cell-based matrices are covered under this segment. The applications in the segment are based on the division of entire skeleton structure into Trauma for fractures; -CMF for cranio maxillofacial (excluding the dental market which is covered within a different market); spinal fusions (since all spinal fusions will need some amount of bone graft usage), and joint reconstruction and replacements (including repairs) for large joints which includes hip and knee, and other joints which include shoulder, elbow, wrist, digit and ankle. Allograft bone chips are the transplanted bones, sourced from a genetically non-identical living or dead member of the same species. Bone Morphogenetic Proteins (BMPs) are low molecular weight, non-collagenous glycoproteins. The cell-based matrices products are a new type of bone substitutes that was introduced to the US market in mid to late 2000s. Demineralized Bone Matrix (DBM) is a form of highly processed allograft bone consisting of collagens, non-collagenous proteins, BMPs and other growth factors that bestow it with both osteoconductive and osteoinductive properties. Synthetic bone graft substitutes are used as substitutes to autograft and allograft bone.

The bone grafts and substitutes market in Finland can expand or contract due to a variety of reasons including population demographics, disease incidence and prevalence, macroeconomic issues, and geopolitical considerations. Disruption to a market could be caused by a sudden, unexpected change in these factors, but it could also be driven by changes in clinical practice, leading to a change in diagnosis or treatment of patients, as part of a process to generally improve medical practice.

For the latest analysis of the market size bone grafts and substitutes in Finland, buy the report here.

Data Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Medical Intelligence Center Market Models are the gold standard of medical device market valuation, company share estimation and market trend forecasting. GlobalData uses a patient-based forecast model or installed base methodology to determine the market size for therapeutic indications and capital equipment expenditures. Estimates are based on a number of sources, including primary research—KOL and industry contact interviews—and secondary research, such as company reports, press releases, published articles, proprietary databases, and general news media.